Integral Derivatives’s Immunogen Inc IMGN Stock Holding History

Integral Derivatives’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-34,769	Closed	-$71K	–	1424
2016 Q4	$71K	Buy	+34,769	New	+$69.8K	﹤0.01%	1080

Other funds holding IMGN

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Integral Derivatives's IMGN Position: Q1 2017 in Review

Integral Derivatives sold out of Immunogen Inc (IMGN) in Q1 2017, closing a stake of 34,769 shares — an estimated $71K sold.

Integral Derivatives first reported a position in IMGN in Q4 2016 and held it in 1 quarter. The position peaked at $71K in Q4 2016. 135 funds tracked by Wall St. Rank hold IMGN as of Q1 2017.

Integral Derivatives reported no remaining Immunogen Inc position as of Q1 2017 after selling out during the quarter.
Integral Derivatives sold 34,769 Immunogen Inc shares in Q1 2017, an estimated $71K.
Integral Derivatives first reported a position in Immunogen Inc in Q4 2016 and held it in 1 quarter.
Integral Derivatives's Immunogen Inc position peaked at $71K in Q4 2016.
135 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2017.

Based on Integral Derivatives's 13F filing for Q1 2017, filed 15 May 2017.